QL
MLYS icon

Quarry LP’s Mineralys Therapeutics MLYS Stock Holding History

Quarry LP’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$271K Buy
+10,000
New +$293K 0.05% 263
2025
Q2 		– Sell
-7,000
Closed -$111K – 1935
2025
Q1 		$111K Buy
+7,000
New +$80.5K 0.02% 483

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Quarry LP's MLYS Position: Q1 2026 in Review

Quarry LP opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 10,000 shares worth $271K. The stake represents 0.05% of the portfolio and ranks #263 among its holdings. This is a return to the name: Quarry LP previously reported a position in MLYS as recently as Q1 2025.

Quarry LP first reported a position in MLYS in Q1 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Quarry LP held 10,000 shares of Mineralys Therapeutics worth $271K as of Q1 2026.
  • Mineralys Therapeutics was a new Quarry LP position in Q1 2026.
  • Mineralys Therapeutics made up 0.05% of Quarry LP's portfolio in Q1 2026, its #263 holding.
  • Quarry LP first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Quarry LP's 13F filing for Q1 2026, filed 15 May 2026.